Real-time · AI · Cross-signal
Biocytogen Pharmaceuticals (Beijing) Ltd just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Biocytogen Pharmaceuticals (Beijing) Ltd, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload BsADC Program
Jul 31, 2024•almost 2 years ago
Contract Type
agreement
BeijingBiotechnologyDescription
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. The partnership aims to explore the combination of potential first-in-class ADC and IDEAYA’s DDR small molecules to enhance the precision and potency of ADCs.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months